publication venue for
- Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease. 2016
- Validation of a modified rapid test to detect the cefazolin inoculum effect in methicillin-susceptible Staphylococcus aureus from bloodstream infections in hospitals from North and Latin America.. 80. 2025
- Increased mortality in hospital- compared to community-onset carbapenem-resistant enterobacterales infections.. 79. 2024
- Initial micafungin treatment does not improve outcomes compared to fluconazole treatment in immunocompromised and critically ill patients with candidaemia.. 79. 2024
- Bone changes with candidate PrEP regimens containing tenofovir disoproxil fumarate and/or maraviroc and/or emtricitabine in US men and women: HPTN 069/ACTG A5305. 2021
- Apramycin resistance in epidemic carbapenem-resistant Klebsiella pneumoniae ST258 strains.. 76. 2021
- Evaluation of in vitro activity of ceftazidime/avibactam and ceftolozane/tazobactam against MDR Pseudomonas aeruginosa isolates from Qatar.. 74. 2019
- Comparable viral decay with initial dolutegravir plus lamivudine versus dolutegravir-based triple therapy.. 74. 2019
- In vitro activity of ampicillin and ceftriaxone against ampicillin-susceptible Enterococcus faecium.. 74. 2019
- Dolutegravir plus lamivudine for initial treatment of HIV-1-infected participants with HIV-1 RNA <500 000 copies/mL: week 48 outcomes from ACTG 5353.. 74. 2019
- Cross-resistance to lincosamides, streptogramins A and pleuromutilins in Streptococcus agalactiae isolates from the USA.. 72. 2017
- Pharmacodynamics of colistin and fosfomycin: a 'treasure trove' combination combats KPC-producing Klebsiella pneumoniae.. 72. 2017
- Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease.. 71. 2015
- In vitro interactions between farnesol and fluconazole, amphotericin B or micafungin against Candida albicans biofilms.. 70. 2014
- Functional CYP2B6 variants and virologic response to an efavirenz-containing regimen in Port-au-Prince, Haiti.. 69. 2014
- Pharmacokinetics of a CCR5 inhibitor in rhesus macaques following vaginal, rectal and oral application.. 69. 2013
- Pharmacokinetics and efficacy of a vaginally administered maraviroc gel in rhesus macaques.. 68. 2012
- Partial protection against multiple RT-SHIV162P3 vaginal challenge of rhesus macaques by a silicone elastomer vaginal ring releasing the NNRTI MC1220.. 68. 2012
- Microbiological and clinical characteristics of vancomycin-resistant Enterococcus faecium bacteraemia in Taiwan: implication of sequence type for prognosis.. 67. 2012
- Efficacy and safety of rilpivirine in treatment-naive, HIV-1-infected patients with hepatitis B virus/hepatitis C virus coinfection enrolled in the Phase III randomized, double-blind ECHO and THRIVE trials.. 67. 2012
- Trends of transmitted drug resistance of HIV-1 and its impact on treatment response to first-line antiretroviral therapy in Taiwan.. 67. 2012
- Metabolic syndrome among HIV-infected Taiwanese patients in the era of highly active antiretroviral therapy: prevalence and associated factors.. 67. 2012
- Impact of antimicrobial stewardship programme changes on unnecessary double anaerobic coverage therapy.. 66. 2011
- Plasmid comparison and molecular analysis of Klebsiella pneumoniae harbouring bla(KPC) from New York City and Toronto.. 66. 2011
- Characterization of blaKPC-containing Klebsiella pneumoniae isolates detected in different institutions in the Eastern USA.. 63. 2009
- Reversion to susceptibility in a linezolid-resistant clinical isolate of Staphylococcus aureus.. 54. 2004
- Distribution across the USA of macrolide resistance and macrolide resistance mechanisms among Streptococcus pneumoniae isolates collected from patients with respiratory tract infections: PROTEKT US 2001-2002.. 54 Suppl 1. 2004
- Clinical and bacteriological efficacy and safety of 5 and 7 day regimens of telithromycin once daily compared with a 10 day regimen of clarithromycin twice daily in patients with mild to moderate community-acquired pneumonia.. 54. 2004
- Emergence of fluoroquinolone resistance among Bacteroides species.. 52. 2003
- The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents.. 52. 2003
- In vitro activity of gatifloxacin alone and in combination with cefepime, meropenem, piperacillin and gentamicin against multidrug-resistant organisms.. 51. 2003
- Fitness of in vitro selected Pseudomonas aeruginosa nalB and nfxB multidrug resistant mutants.. 50. 2002
- A randomized controlled trial of azithromycin versus doxycycline/ciprofloxacin for the syndromic management of sexually transmitted infections in a resource-poor setting.. 49. 2002
- Piperacillin/tazobactam plus tobramycin versus ceftazidime plus tobramycin for the treatment of patients with nosocomial lower respiratory tract infection. Piperacillin/tazobactam Nosocomial Pneumonia Study Group.. 43. 1999
- Enhancement of drug susceptibility of multi-drug resistant strains of Mycobacterium tuberculosis by ethambutol and dimethyl sulphoxide.. 35. 1995
- Adjunctive therapies for community-acquired pneumonia: a systematic review. 2008
- Administration of antimicrobials via the respiratory tract for the treatment of patients with nosocomial pneumonia: a meta-analysis. 2007
- Echinocandin prophylaxis in patients undergoing haematopoietic cell transplantation and other treatments for haematological malignancies. 2018
- Preventing HIV-1 sexual transmission--not sexy enough science, or no benefit to the bottom line? 2003
- New directions in the diagnosis and treatment of pelvic inflammatory disease. 1993